Roche’s fenebrutinib demonstrated near-complete suppression of disease activity and disability progression

New Phase II data show vast majority of patients experiencing no relapses or disability progression

Roche’s PiaSky approved in the EU for treatment of people with PNH

PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration

Royal Sense launches multiple products in pharmaceutical category

Launches Opentop 40, Opentop D, Opentop L, Opentop Dsr and Cefix 200 which are available for sale

Roche’s PiaSky approved in the EU as the first monthly subcutaneous treatment for people with PNH

PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration

BioIVT acquires ZenBio

ZenBio is a highly regarded science-focused company specializing in biospecimens and related services with scientific expertise

BioAge appoints former GSK CEO Jean-Pierre Garnier as Chair of its Board of Directors

New Chair brings extensive experience in global pharmaceutical and biotechnology leadership, healthcare innovation, and strategic drug development

Aayush Wellness enters nutraceutical market with Dreamy Sleep Gummies

FMD vaccination of pastoral sheep and goat to be extended pan India: Animal Husbandry Minister

CIDSCON 2024 discusses actionable efforts to tackle antimicrobial resistance

The emergence of new infections in India is a growing concern

Imfinzi approved in the US for the treatment of resectable non-small cell lung cancer

Based on AEGEAN Phase III trial results which showed Imfinzi-based regimen reduced the risk of recurrence, progression or death by 32% vs. neoadjuvant chemotherapy alone